Mono Pharmacare Ltd

Mono Pharmacare exhibited strong financial growth from March 2024 to March 2025, with net sales rising from 122.34 Cr to 168.34 Cr and profit after tax increasing from 2.46 Cr to 3.11 Cr, despite ongoing negative cash flow from operating activities. Total liabilities and debt also increased, but current assets improved, indicating better liquidity.

As of 19-Nov, Mono Pharmacare Ltd's stock price is Rs 19.70, down 3.67%, with significant underperformance reflected in a year-to-date decline of 43.15%. The stock is trading below all key moving averages and is close to its 52-week low, indicating a bearish trend despite increased investor participation.

Mono Pharmacare's historical performance from March 2024 to March 2025 showed significant growth, with net sales increasing to 168.34 Cr and profit after tax rising to 3.11 Cr, despite challenges in cash flow management. Total assets and liabilities both grew to 110.01 Cr, indicating overall financial expansion.

As of November 10, 2025, Mono Pharmacare is considered overvalued with a valuation grade of expensive, reflected by its PE Ratio of 11.72 and underperformance of 43.84% compared to the Sensex's 5.91% gain, especially when compared to peers like Sun Pharma and Cipla.

As of November 6, 2025, Mono Pharmacare is considered very expensive and overvalued due to its PE Ratio of 11.72 and EV to EBITDA of 11.68, which, despite appearing reasonable, do not align with its peers like Sun Pharma and Cipla, and its significant year-to-date stock underperformance of -40.84% further supports this conclusion.

As of 15-Oct, Mono Pharmacare Ltd's stock price is Rs 21.00, down 1.87%, with significant underperformance reflected in a -7.89% return over the past week and -14.11% over the past month. The stock is trading below all key moving averages and is near its 52-week low, indicating a bearish trend amidst a generally stable market.

As of 25-Sep, Mono Pharmacare Ltd's stock price is at 22.25, down 8.25%, and has underperformed its sector and the benchmark Sensex significantly. The stock has declined by 35.79% year-to-date, with no indicators of a positive sentiment shift.

As of September 23, 2025, Mono Pharmacare is considered overvalued with a PE ratio of 13.87, a significant decline of 30.01% year-to-date, and a valuation grade shift from fair to expensive compared to its industry peers.

As of September 22, 2025, Mono Pharmacare is fairly valued with a PE ratio of 13.15, significantly lower than its peers, indicating strong growth potential despite a year-to-date stock decline of 30.01%.

As of September 18, 2025, Mono Pharmacare is considered overvalued with a valuation grade of expensive, supported by a PE ratio of 13.69 and underwhelming stock performance, particularly when compared to peers like Sun Pharma and Cipla.

As of September 17, 2025, Mono Pharmacare is fairly valued with a PE ratio of 13.69, an EV to EBITDA of 12.47, and a PEG ratio of 0.51, making it a more attractive investment compared to peers like Sun Pharma and Divi's Lab, despite a year-to-date decline of -30.88%.

As of September 16, 2025, Mono Pharmacare is considered overvalued with a PE ratio of 14.58 and a year-to-date return of -29.58%, especially when compared to peers like Sun Pharma and Divi's Lab, which are much more expensive.

As of September 15, 2025, Mono Pharmacare is fairly valued with a PE ratio of 13.32 and an EV to EBITDA of 10.78, making it more attractive than peers like Sun Pharma and Divi's Lab, despite a year-to-date return of -29.44%, it has recently outperformed the Sensex with a 13.46% return over the past week.

As of September 10, 2025, Mono Pharmacare is considered overvalued with a valuation grade of expensive, reflected by a PE ratio of 13.44 and a year-to-date return of -32.18%, significantly underperforming compared to industry peers like Sun Pharma and Cipla.

As of 09-Sep, Mono Pharmacare Ltd's stock price is at 20.65, down 4.18%, and has underperformed its sector by 4.81%. Despite a significant year-to-date decline of 40.40%, investor participation has increased, with delivery volume up 275% compared to the 5-day average.

As of 08-Sep, Mono Pharmacare Ltd's stock price is Rs. 21.55, down 4.22%, with a significant decline over the past year and reduced investor interest. The stock is trading below all major moving averages, indicating a bearish trend with no immediate catalysts for recovery.

As of 05-Sep, Mono Pharmacare Ltd is priced at 22.50 with no change, indicating a downward trend as it trades below all key moving averages. The stock has decreased by 6.83% over the past month and 35.06% year-to-date, underperforming compared to the benchmark Sensex, which has increased by 1.29% in the same period.

As of 04-Sep, Mono Pharmacare Ltd is priced at 22.50, showing no change and a 0.00% movement. The stock has underperformed significantly, with a 35.06% drop year-to-date and a bearish trend indicated by trading below all major moving averages.

As of 03-Sep, Mono Pharmacare Ltd is priced at 22.50 with no change, underperforming its sector and trading below all key moving averages. The stock has declined 10.00% over the past month and 35.06% year-to-date, contrasting sharply with the Sensex's positive performance.